The complications of vasculitis and its treatment

Ntatsaki, 2010, Epidemiology of ANCA-associated vasculitis, Rheum Dis Clin N Am, 36, 447, 10.1016/j.rdc.2010.04.002 Watts, 2015, Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, Nephrol Dial Transplant, 30, i14, 10.1093/ndt/gfv022 Walton, 1958, Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis), Br Med J, 2, 265, 10.1136/bmj.2.5091.265 Jennette, 2013, L17. What can we expect from the revised Chapel Hill consensus conference nomenclature of vasculitis?, Presse Med, 42, 550, 10.1016/j.lpm.2013.01.016 Flossmann, 2011, Long-term patient survival in ANCA-associated vasculitis, Ann Rheum Dis, 70, 488, 10.1136/ard.2010.137778 Yates, 2016, EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis, Ann Rheum Dis, 75, 1583, 10.1136/annrheumdis-2016-209133 Rhee, 2016, Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease, Arthritis Rheumatol, 68, 1711, 10.1002/art.39614 Little, 2010, Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis, Ann Rheum Dis, 69, 1036, 10.1136/ard.2009.109389 Robson, 2015, Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials, Ann Rheum Dis, 74, 177, 10.1136/annrheumdis-2013-203927 Exley, 1997, Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides, Arthritis Rheum, 40, 371, 10.1002/art.1780400222 Seo, 2005, Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET), Arthritis Rheum, 52, 2168, 10.1002/art.21117 Hoffman, 1992, The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate, Arthritis Rheum, 35, 1322, 10.1002/art.1780351113 Booth, 2003, Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study, Am J Kidney Dis, 41, 776, 10.1016/S0272-6386(03)00025-8 Day, 2010, Prediction of ESRD in pauci-immune necrotizing glomerulonephritis: quantitative histomorphometric assessment and serum creatinine, Am J Kidney Dis, 55, 250, 10.1053/j.ajkd.2009.10.047 Berden, 2010, Histopathologic classification of ANCA-associated glomerulonephritis, J Am Soc Nephrol, 21, 1628, 10.1681/ASN.2010050477 Lee, 2014, Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure, Clin J Am Soc Nephrol, 9, 905, 10.2215/CJN.08290813 Walsh, 2012, Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis, Arthritis Rheum, 64, 542, 10.1002/art.33361 Wojciechowska, 2016, Granulomatosis with polyangiitis in otolaryngologist practice: a review of current knowledge, Clin Exp Otorhinolaryngol, 9, 8, 10.21053/ceo.2016.9.1.8 Laudien, 2009, Olfactory dysfunction in Wegener's granulomatosis, Rhinology, 47, 254, 10.4193/Rhin08.159 Alba, 2017, Interstital lung disease in ANCA vasculitis, Autoimmun Rev, 16, 722, 10.1016/j.autrev.2017.05.008 Englund, 2016, Comorbidities in patients with antineutrophil cytoplasmic antibody-associated vasculitis versus the general population, J Rheumatol, 43, 1553, 10.3899/jrheum.151151 Merkel, 2005, Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) study, Ann Intern Med, 142, 620, 10.7326/0003-4819-142-8-200505030-00011 Kronbichler, 2016, Letter to the editor: "Risk of venous thromboembolism among patients with vasculitis: a systematic review and meta-analysis", Clin Rheumatol, 35, 2867, 10.1007/s10067-016-3418-3 Stassen, 2008, Venous thromboembolism in ANCA-associated vasculitis--incidence and risk factors, Rheumatology (Oxford), 47, 530, 10.1093/rheumatology/ken035 Berden, 2010, Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis, J Am Soc Nephrol, 21, 2169, 10.1681/ASN.2010030274 Basu, 2014, The characterisation and determinants of quality of life in ANCA associated vasculitis, Ann Rheum Dis, 73, 207, 10.1136/annrheumdis-2012-202750 Morgan, 2017, Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse, Arthritis Res Ther, 19, 129, 10.1186/s13075-017-1321-1 de Joode, 2017, Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data, Rheumatology (Oxford), 56, 1894, 10.1093/rheumatology/kex281 Sanders, 2016, Nephrol Dial Transplant, 31, 1453, 10.1093/ndt/gfw211 Karras, 2017, Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis, Ann Rheum Dis, 76, 1662, 10.1136/annrheumdis-2017-211123 Faurschou, 2008, Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients, J Rheumatol, 35, 100 Heijl, 2011, Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials, Ann Rheum Dis, 70, 1415, 10.1136/ard.2010.145250 Mohammad, 2017, Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis, J Rheumatol, 44, 1468, 10.3899/jrheum.160909 McGregor, 2015, Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function, Nephrol Dial Transplant, 30, i171, 10.1093/ndt/gfv045 van Assen, 2011, EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases, Ann Rheum Dis, 70, 414, 10.1136/ard.2010.137216 Jones, 2010, Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis, N Engl J Med, 363, 211, 10.1056/NEJMoa0909169 Stone, 2010, Rituximab versus cyclophosphamide for ANCA-associated vasculitis, N Engl J Med, 363, 221, 10.1056/NEJMoa0909905 Alberici, 2015, Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis, Rheumatology (Oxford), 54, 1153, 10.1093/rheumatology/keu452 Charlier, 2009, Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients, Ann Rheum Dis, 68, 658, 10.1136/ard.2008.088302 McGregor, 2012, Vasculitis: the elusive optimal induction strategy for vasculitis, Nat Rev Nephrol, 8, 195, 10.1038/nrneph.2012.16 Walsh, 2013, Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial, Trials, 14, 73, 10.1186/1745-6215-14-73 Pagnoux, 2015, Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of glucocorticoid and cyclophosphamide-based induction therapy, Arthritis Rheumatol, 67, 1117, 10.1002/art.39011 Wong, 2015, Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis, Nephrol Dial Transplant, 30, i164 Harper, 2005, ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients, Rheumatology (Oxford), 44, 495, 10.1093/rheumatology/keh522 Trivin, 2017, Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease, Clin Kidney J, 10, 461 Heusele, 2014, Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab, Clin Rheumatol, 33, 799, 10.1007/s10067-014-2509-2 David Morgan, 2016, Association of low B cell count and IgG levels with infection, and poor vaccine response with all-cause mortality in an immunosuppressed vasculitis population, Arthritis Care Res (Hoboken), 68, 853, 10.1002/acr.22757 Tesfa, 2011, Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms, Expert Rev Hematol, 4, 619, 10.1586/ehm.11.62 Salmon, 2015, Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry, RMD Open, 1, e000034, 10.1136/rmdopen-2014-000034 Freeley, 2013, Granulocyte colony stimulating factor exacerbates antineutrophil cytoplasmic antibody vasculitis, Ann Rheum Dis, 72, 1053, 10.1136/annrheumdis-2012-202160 Roberts, 2015, Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease, J Autoimmun, 57, 60, 10.1016/j.jaut.2014.11.009 Lund, 2006, B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection, J Immunol, 176, 6147, 10.4049/jimmunol.176.10.6147 Ntatsaki, 2014, BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis, Rheumatology (Oxford), 53, 2306, 10.1093/rheumatology/ket445 Droz, 2013, Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases, Arthritis Care Res (Hoboken), 65, 1504, 10.1002/acr.21990 Shouval, 2013, Immunosuppression and HBV reactivation, Semin Liver Dis, 33, 167, 10.1055/s-0033-1345722 Perrillo, 2015, American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy, Gastroenterology, 148, 221, 10.1053/j.gastro.2014.10.038 Sebastiani, 2017, Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis, Joint Bone Spine, 84, 525, 10.1016/j.jbspin.2017.05.013 Bharat, 2012, Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases, Arthritis Care Res (Hoboken), 64, 612, 10.1002/acr.21564 Pugnet, 2013, Progressive multifocal encephalopathy after cyclophosphamide in granulomatosis with polyangiitis (Wegener) patients: case report and review of literature, Clin Exp Rheumatol, 31, S62 Holvast, 2009, Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination, Ann Rheum Dis, 68, 873, 10.1136/ard.2008.092924 van Assen, 2010, Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab, Arthritis Rheum, 62, 75, 10.1002/art.25033 Bingham, 2010, Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial, Arthritis Rheum, 62, 64, 10.1002/art.25034 Wung, 2005, Herpes zoster in immunocompromised patients: incidence, timing, and risk factors, Am J Med, 118, 1416, 10.1016/j.amjmed.2005.06.012 Willis, 2017, Herpes zoster vaccine live: a 10year review of post-marketing safety experience, Vaccine, 35, 7231, 10.1016/j.vaccine.2017.11.013 Morgan, 2009, Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study, Arthritis Rheum, 60, 3493, 10.1002/art.24957 Filer, 2003, Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa, Ann Rheum Dis, 62, 162, 10.1136/ard.62.2.162 Nakano, 2010, Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study, Am J Kidney Dis, 55, 21, 10.1053/j.ajkd.2009.06.034 Souverein, 2004, Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study, Heart, 90, 859, 10.1136/hrt.2003.020180 Suppiah, 2011, A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis, Arthritis Care Res (Hoboken), 63, 588, 10.1002/acr.20433 Houben, 2018, Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies, Rheumatology (Oxford), 57, 555, 10.1093/rheumatology/kex338 Bramlage, 2017, Management of cardiovascular risk factors in patients with ANCA-associated vasculitis, J Eval Clin Pract, 23, 747, 10.1111/jep.12709 Huong, 2002, Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients, J Rheumatol, 29, 2571 McDermott, 1996, Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide, Ann Rheum Dis, 55, 224, 10.1136/ard.55.4.224 Hickman, 2011, Causes and management of infertility in systemic lupus erythematosus, Rheumatology (Oxford), 50, 1551, 10.1093/rheumatology/ker105 Goldstein, 2007, Pregnancy outcome of women exposed to azathioprine during pregnancy, Birth Defects Res A Clin Mol Teratol, 79, 696, 10.1002/bdra.20399 Machen, 2017, Vasculitis and pregnancy, Rheum Dis Clin N Am, 43, 239, 10.1016/j.rdc.2016.12.005 De Cock, 2017, Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab, Rheumatology (Oxford), 56, 661 Walsh, 2010, Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis, Arthritis Care Res (Hoboken), 62, 1166, 10.1002/acr.20176 Geer, 2014, Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism, Endocrinol Metab Clin N Am, 43, 75, 10.1016/j.ecl.2013.10.005 Donihi, 2006, Prevalence and predictors of glucocorticoid-related hyperglycemia in hospitalized patients, Endocr Pract, 12, 358, 10.4158/EP.12.4.358 Compston, 2017, UK clinical guideline for the prevention and treatment of osteoporosis, Arch Osteoporos, 12, 43, 10.1007/s11657-017-0324-5 Boomsma, 2002, Prevalence of reduced bone mineral density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a cross-sectional study, Osteoporos Int, 13, 74, 10.1007/s198-002-8341-z Buckley, 2017, 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis, Arthritis Care Res (Hoboken), 69, 1095, 10.1002/acr.23279 Homik, 2000, Calcium and vitamin D for glucocorticoid-induced osteoporosis, Cochrane Database Syst Rev, CD000952 Adachi, 2001, Glucocorticoid-Induced osteoporosis: detection and management, Drug Saf, 24, 607, 10.2165/00002018-200124080-00005 Reid, 2009, Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial, Lancet, 373, 1253, 10.1016/S0140-6736(09)60250-6 Jayne, 2017, Randomized trial of C5a receptor inhibitor avacopan in anca-associated vasculitis, J Am Soc Nephrol, 28, 2756, 10.1681/ASN.2016111179